Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

New ketamine study promises extended relief for depression

Written by | 4 Jun 2025

Roughly 10 percent of the U.S. population is afflicted with major depressive disorder at any given time, and up to 20 percent will exhibit MDD symptoms over their lifetimes. Yet… read more.

Patients with clinical depression “stopped seeking treatment” during the COVID waves

Written by | 19 Oct 2022

In the first study of its kind, German researchers have shown that the COVID pandemic saw a huge drop in the number of patients being admitted to hospital… read more.

Psychotherapy found to be ineffective or unavailable for medicated patients with severe depression

Written by | 8 Jun 2022

Antidepressants are the first-choice treatment for severe depression. Antidepressant use is often supplemented by psychotherapy. Now a major ongoing international study has shown that adding psychotherapy treatment to… read more.

Supplemental New Drug Application submitted to FDA for Vraylar for the adjunctive treatment of major depressive disorder – AbbVie

Written by | 10 Apr 2022

AbbVie announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (Vraylar) to the FDA for the adjunctive treatment of major depressive disorder (MDD) in… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.